PortfoliosLab logoPortfoliosLab logo
GSK vs. AVY
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

GSK vs. AVY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in GlaxoSmithKline plc (GSK) and Avery Dennison Corporation (AVY). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, GSK achieves a 9.89% return, which is significantly higher than AVY's -11.44% return. Over the past 10 years, GSK has underperformed AVY with an annualized return of 5.35%, while AVY has yielded a comparatively higher 9.69% annualized return.


GSK

1D
0.34%
1M
6.78%
YTD
9.89%
6M
10.40%
1Y
34.50%
3Y*
19.84%
5Y*
5.34%
10Y*
5.35%

AVY

1D
0.31%
1M
2.60%
YTD
-11.44%
6M
-11.79%
1Y
-6.75%
3Y*
0.06%
5Y*
-4.53%
10Y*
9.69%
*Multi-year figures are annualized to reflect compound growth (CAGR)

GSK vs. AVY - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
GSK
GlaxoSmithKline plc
9.89%51.23%-5.14%9.71%-33.41%26.74%-17.72%29.24%13.79%-2.97%
AVY
Avery Dennison Corporation
-11.44%-0.73%-5.95%13.66%-15.06%41.41%20.86%48.54%-20.28%66.75%

Correlation

The correlation between GSK and AVY is 0.41, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.41

Correlation (3Y)
Calculated over the trailing 3-year period

0.34

Correlation (5Y)
Calculated over the trailing 5-year period

0.32

Correlation (10Y)
Calculated over the trailing 10-year period

0.29

Correlation (All Time)
Calculated using the full available price history since Jul 9, 1986

0.26

The correlation between GSK and AVY shifts across timeframes, from 0.26 (all time) to 0.41 (1 year), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

GSK:

$108.04B

AVY:

$12.26B

EPS

GSK:

£2.85

AVY:

$8.87

PE Ratio

GSK:

13.90

AVY:

17.95

PEG Ratio

GSK:

0.93

AVY:

5.99

PS Ratio

GSK:

2.47

AVY:

1.37

PB Ratio

GSK:

3.42

AVY:

5.33

Total Revenue (TTM)

GSK:

£32.78B

AVY:

$9.01B

Gross Profit (TTM)

GSK:

£23.87B

AVY:

$2.59B

EBITDA (TTM)

GSK:

£11.30B

AVY:

$1.24B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

GSK vs. AVY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GSK
GSK Risk / Return Rank: 7272
Overall Rank
GSK Sharpe Ratio Rank: 7575
Sharpe Ratio Rank
GSK Sortino Ratio Rank: 7171
Sortino Ratio Rank
GSK Omega Ratio Rank: 6969
Omega Ratio Rank
GSK Calmar Ratio Rank: 7272
Calmar Ratio Rank
GSK Martin Ratio Rank: 7373
Martin Ratio Rank

AVY
AVY Risk / Return Rank: 2525
Overall Rank
AVY Sharpe Ratio Rank: 2626
Sharpe Ratio Rank
AVY Sortino Ratio Rank: 2222
Sortino Ratio Rank
AVY Omega Ratio Rank: 2323
Omega Ratio Rank
AVY Calmar Ratio Rank: 2929
Calmar Ratio Rank
AVY Martin Ratio Rank: 2525
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GSK vs. AVY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for GlaxoSmithKline plc (GSK) and Avery Dennison Corporation (AVY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


GSKAVYDifference
Sharpe ratioReturn per unit of total volatility

+1.48

Sortino ratioReturn per unit of downside risk

+2.13

Omega ratioGain probability vs. loss probability

1.20

0.95

+0.25

Calmar ratioReturn relative to maximum drawdown

1.58

-0.43

+2.01

Martin ratioReturn relative to average drawdown

3.92

-0.91

+4.83

GSK vs. AVY - Sharpe Ratio Comparison

The current GSK Sharpe Ratio is 1.09, which is higher than the AVY Sharpe Ratio of -0.39. The chart below compares the historical Sharpe Ratios of GSK and AVY, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

GSK vs. AVY - Drawdown Comparison

The maximum GSK drawdown since its inception was -55.70%, smaller than the maximum AVY drawdown of -73.03%. Use the drawdown chart below to compare losses from any high point for GSK and AVY.


Loading charts...

Drawdown Indicators


GSKAVYDifference

Max Drawdown

Largest peak-to-trough decline

-55.70%

-73.03%

+17.33%

Max Drawdown (1Y)

Largest decline over 1 year

-18.63%

-21.62%

+2.99%

Max Drawdown (3Y)

Largest decline over 3 years

-28.46%

-30.56%

+2.10%

Max Drawdown (5Y)

Largest decline over 5 years

-50.10%

-31.80%

-18.30%

Max Drawdown (10Y)

Largest decline over 10 years

-50.10%

-43.52%

-6.58%

Current Drawdown

Current decline from peak

-11.92%

-27.73%

+15.81%

Average Drawdown

Average peak-to-trough decline

-18.87%

-16.79%

-2.08%

Ulcer Index

Depth and duration of drawdowns from previous peaks

8.28%

10.16%

-1.88%

Volatility

GSK vs. AVY - Volatility Comparison

The current volatility for GlaxoSmithKline plc (GSK) is 6.81%, while Avery Dennison Corporation (AVY) has a volatility of 7.39%. This indicates that GSK experiences smaller price fluctuations and is considered to be less risky than AVY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


GSKAVYDifference

Volatility (1M)

Calculated over the trailing 1-month period

6.81%

7.39%

-0.58%

Volatility (6M)

Calculated over the trailing 6-month period

18.49%

16.29%

+2.20%

Volatility (1Y)

Calculated over the trailing 1-year period

27.06%

23.82%

+3.24%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

25.08%

24.68%

+0.40%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

22.89%

27.06%

-4.17%

Dividends

GSK vs. AVY - Dividend Comparison

GSK's dividend yield for the trailing twelve months is around 3.26%, more than AVY's 2.40% yield.


PositionTTM20252024202320222021202020192018201720162015
AVY
Avery Dennison Corporation
2.40%2.03%1.84%1.57%1.62%1.23%1.52%1.73%2.24%1.53%2.28%2.33%
GSK
GlaxoSmithKline plc
3.26%3.42%4.60%3.75%5.47%4.99%5.59%4.35%5.65%5.83%6.86%5.93%

Financials

GSK vs. AVY - Financials Comparison

This section allows you to compare key financial metrics between GlaxoSmithKline plc and Avery Dennison Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


2.00B4.00B6.00B8.00B10.00B20222023202420252026
7.63B
2.30B
(GSK) Total Revenue
(AVY) Total Revenue
Please note, different currencies. GSK values in GBP, AVY values in USD

GSK vs. AVY - Profitability Comparison

The chart below illustrates the profitability comparison between GlaxoSmithKline plc and Avery Dennison Corporation over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

20.0%30.0%40.0%50.0%60.0%70.0%80.0%20222023202420252026
75.4%
28.9%
Portfolio components
GSK - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported a gross profit of 5.75B and revenue of 7.63B. Therefore, the gross margin over that period was 75.4%.

AVY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Avery Dennison Corporation reported a gross profit of 664.80M and revenue of 2.30B. Therefore, the gross margin over that period was 28.9%.

GSK - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported an operating income of 2.29B and revenue of 7.63B, resulting in an operating margin of 30.1%.

AVY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Avery Dennison Corporation reported an operating income of 271.90M and revenue of 2.30B, resulting in an operating margin of 11.8%.

GSK - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported a net income of 1.74B and revenue of 7.63B, resulting in a net margin of 22.8%.

AVY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Avery Dennison Corporation reported a net income of 168.10M and revenue of 2.30B, resulting in a net margin of 7.3%.


Frequently Asked Questions


GSK and AVY have a correlation of 0.41, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

AVY has higher volatility (7.39%) compared to GSK (6.81%). In terms of maximum drawdown, GSK dropped -55.70% vs AVY's -73.03%.

GSK currently has the higher Sharpe Ratio (1.09 vs -0.39), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for GSK and AVY

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer